The Biden administration has announced the first 10 drugs that will be subject to Medicare price negotiations, a new policy that aims to lower the costs of prescription drugs for millions of Americans.

The 10 drugs are:

•  Eliquis: A blood thinner that prevents blood clots and strokes. It is one of the most expensive drugs in Medicare, costing about $10 billion in 2020.

•  Jardiance: A diabetes drug that lowers blood sugar and reduces the risk of cardiovascular complications. It is also one of the most expensive drugs in Medicare, costing about $5 billion in 2020.

•  Xarelto: Another blood thinner that prevents blood clots and strokes. It is also one of the most expensive drugs in Medicare, costing about $4 billion in 2020.

•  Januvia: A diabetes drug that lowers blood sugar and stimulates insulin production. It is also one of the most expensive drugs in Medicare, costing about $3 billion in 2020.

•  Farxiga: A diabetes drug that lowers blood sugar and reduces the risk of heart failure and kidney disease. It is also one of the most expensive drugs in Medicare, costing about $2 billion in 2020.

•  Entresto: A heart failure drug that improves blood flow and reduces the strain on the heart. It is also one of the most expensive drugs in Medicare, costing about $2 billion in 2020.

•  Enbrel: An autoimmune disease drug that treats rheumatoid arthritis, psoriasis, and other inflammatory conditions. It is also one of the most expensive drugs in Medicare, costing about $2 billion in 2020.

•  Imbruvica: A cancer drug that treats leukemia, lymphoma, and other blood cancers. It is also one of the most expensive drugs in Medicare, costing about $2 billion in 2020.

•  Stelara: Another autoimmune disease drug that treats psoriasis, Crohn’s disease, and other inflammatory conditions. It is also one of the most expensive drugs in Medicare, costing about $2 billion in 2020.

•  Novolog: A fast-acting insulin that helps control blood sugar levels after meals. It is also one of the most expensive drugs in Medicare, costing about $2 billion in 2020.

The government will negotiate new prices for these drugs with the manufacturers, but the lower prices will not take effect until 2026.

The drugmakers have opposed this policy and have filed lawsuits to stop it, arguing that it is unconstitutional and harmful to innovation.

The Biden administration has defended this policy as a way to make drugs more affordable and accessible for Americans, especially seniors who rely on Medicare for their healthcare needs.

Support The Readers Bureau. Buy A T-Shirt Today (4 different colors)! click  https://www.bonfire.com/one-love-72/?fbclid=IwAR2bod-XSyrCPutOwG_SMnKiInk6Bqe2kCtjBsAFISqHluQcujrF2UUkFew

Readers Bureau, Contributor

 Edited by Jesus Chan

 Do you want to add feedback to this story?

Please add a comment in the box below or send an email to xdeefix@aol.com. Call us at 646-874-7976. SUBSCRIBE CLICK https://www.youtube.com/c/yvadbillingsreadersbureau

Like our Facebook page https://www.facebook.com/TheReadersBureau

Follow us on Twitter https://twitter.com/readersbureau21